Loading... Please wait... Loading... Please wait...
ESTIMATED
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Kazia Therapeutics Limited last posted its earnings results on N/A. The company reported $N/A earnings per share for the quarter, missing analysts' consensus estimates of $N/A by $0. The company had revenue of 5 for the quarter and had revenue of 555 for the year. Kazia Therapeutics Limited has generated $-1 earnings per share over the last year ($-1.11 diluted earnings per share) and currently has a price-to-earnings ratio of -0.45. Kazia Therapeutics Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 29th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 12/30/2023 | Q2 2024 | -$0.37 | $5 | 10/26/2023 | Q4 2023 | -$0.32 | $90,306 | $555 | 03/09/2023 | Q2 2023 | -$0.93 | $0 | 09/01/2022 | Q1 2023 | -$0.05 | $0 | 10/17/2022 | Q4 2022 | -$0.89 | $0 | 03/30/2022 | Q3 2022 | -$0.04 | $0 | 12/30/2021 | Q2 2022 | -$1.00 | $10,000 | 09/29/2021 | Q1 2022 | -$0.05 | $5,000 | 10/07/2021 | Q4 2021 | -$0.16 | $15.18 M | 12/30/2020 | Q2 2021 | -$0.59 | $1,170 | 10/22/2020 | Q4 2020 | -$0.82 | $362,429 | 03/30/2020 | Q3 2020 | -$0.04 | $181,214 | 12/30/2019 | Q2 2020 | -$0.90 | $625,681 | 09/29/2019 | Q1 2020 | -$0.04 | $312,841 | 10/21/2019 | Q4 2019 | -$0.68 | $671,756 | 03/30/2019 | Q3 2019 | -$0.03 | $335,878 | 12/30/2018 | Q2 2019 | -$1.14 | $768,244 | 09/29/2018 | Q1 2019 | -$0.06 | $384,122 | 10/24/2018 | Q4 2018 | -$1.34 | $1.55 M | 03/30/2018 | Q3 2018 | -$0.07 | $777,454 |
|---|
A. Kazia Therapeutics Limited has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 29th, 2024 based off last year's report dates.
A. The conference call for Kazia Therapeutics Limited's latest earnings report can be listened to online.
A. The conference call transcript for Kazia Therapeutics Limited's latest earnings report can be read online.
A. Kazia Therapeutics Limited (NASDAQ:KZIA) has a recorded annual revenue of $555.
A. Kazia Therapeutics Limited (NASDAQ:KZIA) has a recorded net income of $555. Kazia Therapeutics Limited has generated $-1.12 earnings per share over the last four quarters.
A. Kazia Therapeutics Limited (NASDAQ:KZIA) has a price-to-earnings ratio of -0.45 and price/earnings-to-growth ratio is -0.03.
